Novo Nordisk’s Phase 3 Zeus trial of ziltivekimab missed the primary endpoint in reducing major adverse cardiovascular events versus placebo. The company reported the mechanism reduced IL-6 pathway activity and lowered high-sensitivity C-reactive protein, but the effect did not translate into statistically meaningful risk reduction across enrolled populations.